JNJ
$243.19
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide.
Intraday
Recent News
Is It Time To Reassess Johnson & Johnson (JNJ) After Strong Multi Year Share Price Gains
If you are wondering whether Johnson & Johnson at around US$243 per share still offers value, the starting point is understanding what the current price is actually implying. The stock has shown modest short term moves, with a 0.2% return over the last week and a small 0.1% decline over the past month, while the 17.3% year to date return and 53.5% return over the past year give a different picture over longer periods. Recent headlines have focused on Johnson & Johnson's portfolio moves,...
Johnson & Johnson (JNJ) Targets Opportunities around Multiple Myeloma with TECVAYLI
Johnson & Johnson (NYSE:JNJ) is one of Goldman Sachs top healthcare stocks. On March 10, Johnson & Johnson (NYSE:JNJ) announced the submission of a Type II variation application to the European Medicines Agency. The company is seeking approval of TECVAYLI (teclistamab) as a potential treatment for relapsed and refractory multiple Myeloma. The company hopes to […]
JNJ's Bladder Cancer Therapy Meets Key Goal in Early-Stage Study
J&J reports phase I study win for Erda-iDRS in NMIBC, showing strong response rates, durable control and manageable safety as mid-to-late-stage studies advance.
Citi Lifts PT on Johnson & Johnson (JNJ) to $274 From $250 – Here’s Why
Johnson & Johnson (NYSE:JNJ) is one of the most profitable blue chip stocks to invest in now. On March 11, Citi lifted the price target on Johnson & Johnson (NYSE:JNJ) to $274 from $250 while maintaining a Buy rating on the shares. The firm told investors in a research note that it adjusted price targets […]
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference
Executives from Contineum Therapeutics (NASDAQ:CTNM) outlined the company’s clinical priorities and upcoming catalysts during a presentation at the Leerink Global Healthcare Conference, emphasizing a shift from a discovery platform to a clinical-stage company with two lead programs and multiple tria